We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Regeneron Pharmaceuticals Inc | NASDAQ:REGN | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 12.88 | 1.19% | 1,094.99 | 1,091.00 | 1,100.00 | 1,100.08 | 1,079.0855 | 1,087.89 | 282,365 | 23:07:22 |
From Jul 2019 to Jul 2024
By Matt Grossman
Regeneron Pharmaceuticals Inc. Friday logged a stronger profit and higher revenue in the latest quarter, fueled by growing sales for the company's Eylea eye medication and a small revenue contribution from the company's Covid-19 antibody cocktail.
The Tarrytown, N.Y.-based pharmaceutical company posted a profit of $10.24 a share, compared with $6.93 a share in the same quarter a year earlier. Its net income was $1.15 billion, up from $792 billion in the year-ago quarter
The company's adjusted profit was $9.53 a share. Analysts surveyed by FactSet were expecting an adjusted profit of $8.38 a share.
Revenue was $2.42 billion, a 30% increase from $1.86 billion in the fourth quarter of 2019. Analysts had forecast revenue of $2.42 billion.
REGEN-COV, the company's antibody cocktail for Covid-19, generated sales in the quarter of $146 million in the quarter, contributing to sales of $186 million for the product during all of 2020. Regeneron's Eylea eye medication was responsible for $1.34 billion in sales, up from $1.22 billion in the year-ago quarter.
Research and development costs grew 35% to $745 million.
Write to Matt Grossman at matt.grossman@wsj.com
(END) Dow Jones Newswires
February 05, 2021 07:01 ET (12:01 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Regeneron Pharmaceuticals Chart |
1 Month Regeneron Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
